LBPH (Longboard Pharmaceuticals) Research & Development : $67.26 Mil (TTM As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Longboard Pharmaceuticals Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Longboard Pharmaceuticals's Research & Development for the three months ended in Sep. 2024 was $21.45 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 was $67.26 Mil.

Longboard Pharmaceuticals Research & Development Historical Data

The historical data trend for Longboard Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Longboard Pharmaceuticals Research & Development Chart

Longboard Pharmaceuticals Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Research & Development

4.63

19.77

34.64

43.75

Longboard Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Research & Development	Get a 7-Day Free Trial														10.49	12.20	13.17	20.45	21.45

Longboard Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $67.26 Mil.

Longboard Pharmaceuticals (NAS:LBPH) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Longboard Pharmaceuticals Research & Development Related Terms

Thank you for viewing the detailed overview of Longboard Pharmaceuticals's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Longboard Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Longboard Pharmaceuticals Inc (NAS:LBPH) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

N/A

Address

4275 Executive Square, Suite 950, La Jolla, CA, USA, 92037

Website

https://www.longboardpharma.com

Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies.

Executives

Randall Kaye	officer: CMO	11388 SORRENTO VALLEY ROAD, STE. 200, SAN DIEGO CA 92121
Arena Pharmaceuticals Inc	10 percent owner	6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Jane Tiller	director	C/O LONGBOARD PHARMACEUTICALS, INC., 4275 EXECUTIVE DRIVE, SUITE 950, LA JOLLA CA 92037
Brandi Roberts	officer: Chief Financial Officer	12390 EL CAMINO REAL #150, SAN DIEGO CA 92130
Phillip M Schneider	director	GEN-PROBE INCORPORATED, 10210 GENETIC CENTER DRIVE, SAN DIEGO CA 92121
Vincent Aurentz	director	C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Kevin Robert Lind	director, officer: President and CEO	C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Paul J Sekhri	director	C/O VEEVA SYSTEMS INC., 4637 CHABOT DRIVE, SUITE 210, PLEASANTON CA 94588
Casey Lynch	director	C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Le Goff Corinne	director	200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Philip Perera	officer: Chief Medical Officer	C/O LONGBOARD PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121